NUVIGIL is a prescription medicine used to improve wakefulness throughout the day¹…

Tablets are not shown at actual size.

Click here to learn more about taking NUVIGIL.

in adults with excessive sleepiness (ES) associated with:

• Treated obstructive sleep apnea (OSA)
• Shift work sleep disorder, also known as shift work disorder (SWD)
• Narcolepsy

Wakefulness throughout the day with NUVIGIL¹

• NUVIGIL was studied in four 12-week clinical trials
• The clinical trials included over 1100 patients with these disorders
• People who took NUVIGIL experienced significant improvement in wakefulness
• In 2 studies of people with treated OSA and a study of people with narcolepsy, NUVIGIL was tested using the Maintenance of Wakefulness Test (MWT), 4 times throughout the day. In these studies, the measures were taken between 9 am and 3 pm^1-4
• In a study of people with SWD, NUVIGIL was tested using the Multiple Sleep Latency Test (MSLT), 4 times throughout the patient's night shift. In this study, the measures were taken between 2 am and 8 am³
• The MWT and MSLT are measures of a person's degree of sleepiness

NUVIGIL improves wakefulness by treating excessive sleepiness associated with treated OSA, SWD, or narcolepsy.

• People experiencing excessive sleepiness associated with treated OSA, SWD, or narcolepsy may report that they are^5-7:
  • Sleepy, tired, fatigued, or have no energy
  • Too tired to spend time with family and friends
  • Struggling to stay awake at work

Find out more about how NUVIGIL can help with ES associated with

• Treated OSA
• SWD
• Narcolepsy

NUVIGIL does not replace sleep and may not stop your ES completely. Only you and your doctor can decide if NUVIGIL is right for you, so make an appointment to see your doctor today.

While NUVIGIL is used to improve wakefulness in patients with treated OSA, SWD, or narcolepsy, it is not used to treat the sleep disorders themselves or their other symptoms or consequences.

NUVIGIL does not affect sleep, as shown in sleep studies.¹

Based on sleep studies that measure nighttime breathing and brain and muscle activity, NUVIGIL does NOT interfere with sleep.

• In these studies, most people (95%) taking NUVIGIL did not report trouble sleeping (5% reported trouble sleeping). 1% of people taking a sugar pill (placebo) reported trouble sleeping

NUVIGIL is generally well tolerated.¹

In clinical studies:

• Most reported side effects were rated as mild to moderate
• Common side effects of NUVIGIL were headache, nausea, dizziness, and trouble sleeping
• 7% of people taking NUVIGIL stopped treatment due to side effects, compared with 4% of people taking a sugar pill (placebo)

NUVIGIL may cause you to have a serious rash or a serious allergic reaction that may result in hospitalization or be life-threatening.

If you develop a rash, hives, sores, swelling, or trouble swallowing or breathing, stop taking NUVIGIL and call your doctor right away or get emergency treatment.

NUVIGIL has not been studied in children under the age of 17. NUVIGIL is not approved for children for any condition.

NUVIGIL is a federally controlled substance [C-IV] because it has the potential to be abused or lead to dependence. Please use NUVIGIL only as directed and keep in a safe place to prevent misuse and abuse.

References: 1. NUVIGIL [prescribing information]. Frazer, PA: Cephalon, Inc; 2008. 2. Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther. 2006;28(5):689-706. 3. Data on file. Cephalon, Inc. 4. Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin. 2006;22(4):761-774. 5. Chervin RD. Sleepiness, fatigue, tiredness, and lack of energy in obstructive sleep apnea. Chest. 2000;118(2):372-379. 6. Institute for Clinical Systems Improvement. Health Care Guideline: Diagnosis and Treatment of Obstructive Sleep Apnea. 6th ed. Bloomington, MN: Institute for Clinical Systems Improvement; 2008. 7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000.